MX2020005332A - Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. - Google Patents
Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion.Info
- Publication number
- MX2020005332A MX2020005332A MX2020005332A MX2020005332A MX2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A MX 2020005332 A MX2020005332 A MX 2020005332A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidinylamino
- polymorphs
- production
- methods
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil-2-(3- metil-4-(4-(metilamino)- 5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonit rilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/062102 WO2019104086A1 (en) | 2017-11-21 | 2018-11-20 | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005332A true MX2020005332A (es) | 2021-01-08 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005332A MX2020005332A (es) | 2017-11-21 | 2018-11-20 | Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (es) |
| EP (1) | EP3717473B1 (es) |
| JP (1) | JP7303821B2 (es) |
| KR (1) | KR102878525B1 (es) |
| CN (1) | CN111819174A (es) |
| AR (1) | AR113893A1 (es) |
| AU (1) | AU2018372180B2 (es) |
| BR (1) | BR112020010215A2 (es) |
| CA (1) | CA3083022A1 (es) |
| CL (1) | CL2020001346A1 (es) |
| CO (1) | CO2020006206A2 (es) |
| CR (1) | CR20200216A (es) |
| EA (1) | EA202091279A1 (es) |
| ES (1) | ES2975319T3 (es) |
| IL (1) | IL274824A (es) |
| JO (1) | JOP20200128A1 (es) |
| MA (1) | MA51222A (es) |
| MX (1) | MX2020005332A (es) |
| MY (1) | MY209751A (es) |
| PE (1) | PE20210157A1 (es) |
| PH (1) | PH12020550700A1 (es) |
| SG (1) | SG11202004733WA (es) |
| TW (1) | TWI823878B (es) |
| UA (1) | UA126414C2 (es) |
| WO (1) | WO2019104086A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200216A (es) | 2017-11-21 | 2021-03-19 | Denali Therapeutics Inc | Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn |
| CA3086182A1 (en) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| MX2023005071A (es) | 2020-10-29 | 2023-05-16 | Merck Sharp & Dohme Llc | Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas. |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
| US12272712B2 (en) | 2022-05-14 | 2025-04-08 | Xintec Inc. | Chip package and method for forming a chip package having first and second stack of dummy metal layers surround the sensing region |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Ｊａｋ抑制劑的局部製劑 |
| DK2576541T3 (en) | 2010-06-04 | 2016-05-30 | Hoffmann La Roche | Aminopyrimidine AS LRRK2 MODULATORS |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| SI2638031T1 (en) * | 2010-11-10 | 2018-02-28 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| ES2592802T3 (es) | 2011-11-29 | 2016-12-01 | F. Hoffmann-La Roche Ag | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de la quinasa LRRK2 para el tratamiento de la enfermedad de Parkinson |
| JP6117816B2 (ja) | 2011-11-29 | 2017-04-19 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体 |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| WO2013079505A1 (en) | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| BR112014026952B1 (pt) | 2012-05-03 | 2022-03-15 | Genentech, Inc | Derivados de aminopirimidina pirazol e composição que os compreende |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| CR20220182A (es) | 2016-06-16 | 2022-06-15 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) |
| CR20200216A (es) * | 2017-11-21 | 2021-03-19 | Denali Therapeutics Inc | Polimorfos y formas sòlidas de un compuesto de pirimidinilamino-pirazol y mèdtodos de producciòn |
-
2018
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 ES ES18881859T patent/ES2975319T3/es active Active
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt active IP Right Grant
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en not_active Ceased
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 KR KR1020207017598A patent/KR102878525B1/ko active Active
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 PH PH1/2020/550700A patent/PH12020550700A1/en unknown
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 MY MYPI2020002460A patent/MY209751A/en unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001346A1 (es) | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción. | |
| CU20170087A7 (es) | Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida | |
| MX2019004951A (es) | Proceso para la preparacion de pirazolo[1,5-a]pirimidinas y sales de estas. | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| MX388606B (es) | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion. | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| CO2020012574A2 (es) | Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| MX394320B (es) | Formas solidas de compuestos de 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituidos | |
| WO2015111085A3 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| MX2020004050A (es) | Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina. | |
| CU20190035A7 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina | |
| MX2020009412A (es) | Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido. | |
| AR103506A1 (es) | Formas sólidas de ácido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido)acético, sus composiciones y usos | |
| CL2017001466A1 (es) | Un proceso para la fabricación de idalopirdina |